• Explore /
  • Poster
  • / Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).

Abstract Poster

Authors

null

Angela DeMichele

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

Angela DeMichele , James J. Harding , Melinda L. Telli , Pamela N. Munster , Rana McKay , Othon Iliopoulos , Keith W. Orford , Mark K. Bennett , James Walter Mier , Taofeek Kunle Owonikoko , Manish R. Patel , Richard D. Carvajal , Funda Meric-Bernstam , Jeffrey R. Infante

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Triple-Negative Breast Cancer

Clinical Trial Registration Number

NCT02071862

Citation

J Clin Oncol 34, 2016 (suppl; abstr 1011)

DOI

10.1200/JCO.2016.34.15_suppl.1011

Abstract #

1011

Poster Bd #

116

Abstract Disclosures

Similar Posters

First Author: Nizar M. Tannir

First Author: James J. Harding

First Author: Funda Meric-Bernstam

Poster

2019 Gastrointestinal Cancers Symposium

CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results.

CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results.

First Author: Kristen Keon Ciombor